Real-World Data Study Launches: Machine Learning to Personalise Advanced NSCLC Treatment Selection — 144,000 Patient Analysis

References

1. 1.University of Utah. (2024). Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data. ClinicalTrials.gov. NCT06934343. https://clinicaltrials.gov/study/NCT06934343
2. 2.Hernán, M. A., & Robins, J. M. (2020). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 189(6), 435-442. https://doi.org/10.1093/aje/kwaa084
3. 3.Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347-1358. https://doi.org/10.1056/NEJMra1814259
4. 4.Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 33-64. https://doi.org/10.3322/caac.21763
5. 5.Reck, M., Rodríguez-Abreu, D., Robinson, A. G., et al. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine, 375(19), 1823-1833. https://doi.org/10.1056/NEJMoa1606774
6. 6.Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. New England Journal of Medicine, 378(22), 2078-2092. https://doi.org/10.1056/NEJMoa1801005